Sutro Biopharma STRO Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Financing Component On Unearned Revenue | $3.15M-40.7% | $3.41M-45.7% | $3.76M-49.8% | $4.38M-49.5% | $5.31M-43.9% | |
| Materials Supply | $10.95M+243% | $11.71M+581% | $10.97M+760% | $8.62M+303% | $3.2M+53.7% | |
| Ongoing Performance Related To Unsatisfied Performance Obligations | $74.94M+79.1% | $75.94M+110% | $75.33M+111% | $74.47M+106% | $41.84M+93.0% | |
| Research And Development Services | $2.12M-52.7% | $2.46M-52.7% | $2.95M-52.5% | $3.7M-46.1% | $4.48M-36.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Sutro Biopharma break its business down?
- Sutro Biopharma (STRO) reports revenue by product across 4 parts — Financing Component On Unearned Revenue, Materials Supply, Ongoing Performance Related To Unsatisfied Performance Obligations and Research And Development Services. Each is extracted from the segment footnotes and tracked over time.
- Where does Sutro Biopharma's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Sutro Biopharma's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
